Jover Placid 4

What Happened
Jover Placid, Executive Vice President and Chief Human Resources Officer of Teva Pharmaceutical Industries Ltd (TEVA), was granted 37,982 restricted share units (RSUs) on March 4, 2026. The grant was reported as a derivative award with an acquisition price of $0.00 (no cash paid at grant). This is a compensation grant (award), not an open‑market purchase or sale.

Key Details

• Transaction date: March 4, 2026; Form 4 filed March 6, 2026 (timely under the two‑business‑day rule).
• Transaction type/code: Grant / Award (A); 37,982 RSUs granted at $0.00.
• Vesting schedule (per filing): 9,495 RSUs vest on each of March 4, 2027, 2028 and 2029; 9,497 RSUs vest on March 4, 2030.
• Footnotes: Each RSU represents a contingent right to one ordinary share or, at the committee's option, the cash value of one ordinary share. Ordinary shares may be represented by American Depositary Shares (ADS), currently 1 ADS = 1 ordinary share.
• Shares owned after transaction: not specified in the provided filing summary.
• No indication of sale or immediate disposition in this filing.

Context
Restricted share units are derivative compensation awards that convert into company stock (or cash) if and when they vest; they do not represent immediate stock ownership or a market purchase. Grants like this reflect compensation decisions by the company's Human Resources and Compensation Committee and should be viewed as part of executive pay rather than a direct insider market signal.